[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-001", "question": "A 45-year-old man with a history of alcoholic cirrhosis presents to the ICU with massive upper gastrointestinal bleeding. Despite endoscopic intervention and octreotide infusion, bleeding persists, and he develops hemodynamic instability. Transjugular intrahepatic portosystemic shunt (TIPS) is considered, but imaging reveals a rare anatomical variant. What is the most appropriate next step in management?", "options": ["Proceed with TIPS using a covered stent to mitigate risks", "Initiate balloon tamponade with a Sengstaken-Blakemore tube", "Administer terlipressin as an alternative vasoconstrictor", "Perform urgent surgical portocaval shunt", "Refer for angiographic embolization of the coronary vein"], "answer": "E", "answer_index": 4, "explanation": "In persistent variceal bleeding with anatomical variants precluding TIPS, angiographic embolization targets specific bleeding vessels like the coronary vein, offering a less invasive option. TIPS is contraindicated due to the variant, while surgical shunts carry high mortality in unstable patients. Terlipressin and balloon tamponade are temporizing but not definitive here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nThe patient has:\n- Alcoholic cirrhosis\n- Massive upper GI bleeding (likely variceal)\n- Failed endoscopic intervention\n- Failed octreotide infusion\n- Hemodynamic instability\n- TIPS is being considered but there's a \"rare anatomical variant\" that apparently precludes it\n\nThe question asks about the next step when TIPS cannot be performed due to anatomical reasons.\n\nLet me evaluate each option:\n\nA. Proceed with TIPS using covered stent - This seems contradictory since the anatomical variant is mentioned as a barrier. However, covered stents can sometimes help in certain situations.\n\nB. Balloon tamponade (Sengstaken-Blakemore tube) - This is a temporizing measure for uncontrolled variceal bleeding when other measures fail. It's a bridge therapy that can control bleeding temporarily while definitive treatment is arranged.\n\nC. Terlipressin - This is another vasoconstrictor similar to octreotide. Since octreotide has already failed, switching to another vasoconstrictor alone is unlikely to be sufficient.\n\nD. Surgical portocaval shunt - This is a definitive treatment but carries high mortality in emergency settings, especially in cirrhotic patients with active bleeding.\n\nE. Angiographic embolization of coronary vein (left gastric vein) - This can be used to control variceal bleeding by embolizing the feeding vessels to varices.\n\nGiven that:\n1. The patient is hemodynamically unstable\n2. Endoscopy and medical therapy have failed\n3. TIPS is not feasible due to anatomical variant\n\nThe most appropriate immediate next step would be balloon tamponade (B) as a bridge/temporizing measure to control bleeding and stabilize the patient. This is the standard rescue therapy when endoscopic and pharmacological treatments fail and TIPS is not immediately available or feasible.\n\nBalloon tamponade can achieve hemostasis in 80-90% of cases temporarily, allowing time for stabilization and planning of definitive treatment.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-002", "question": "A 62-year-old woman with metastatic breast cancer on paclitaxel develops acute dyspnea and hypoxemia. CT angiography shows no pulmonary embolism, but echocardiography reveals right ventricular strain. Bone marrow biopsy confirms tumor infiltration. What is the most likely diagnosis?", "options": ["Paclitaxel-induced pneumonitis", "Tumor microembolism syndrome", "Lymphangitic carcinomatosis", "Chemotherapy-associated pulmonary veno-occlusive disease", "Metastatic tumor thrombus in pulmonary arteries"], "answer": "B", "answer_index": 1, "explanation": "Tumor microembolism syndrome occurs when tumor cells embolize to pulmonary vasculature, causing right heart strain without macroscopic emboli, fitting this presentation in metastatic cancer. Lymphangitic carcinomatosis typically shows interstitial patterns on imaging, while paclitaxel pneumonitis is inflammatory. Veno-occlusive disease is more associated with stem cell transplant regimens.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nKey clinical findings:\n- 62-year-old woman with metastatic breast cancer\n- On paclitaxel chemotherapy\n- Acute dyspnea and hypoxemia\n- CT angiography: NO pulmonary embolism\n- Echocardiography: Right ventricular strain\n- Bone marrow biopsy: Tumor infiltration\n\nAnalysis of options:\n\nA. Paclitaxel-induced pneumonitis: This would typically show interstitial changes on CT and wouldn't specifically cause RV strain without parenchymal findings. The bone marrow involvement is not directly related.\n\nB. Tumor microembolism syndrome: This occurs when tumor cells embolize to the pulmonary microvasculature. It causes acute dyspnea, hypoxemia, and RV strain due to increased pulmonary vascular resistance. Importantly, CT angiography is often NEGATIVE because the emboli are too small to visualize. Bone marrow infiltration indicates widespread metastatic disease with tumor cells in the circulation, supporting this diagnosis.\n\nC. Lymphangitic carcinomatosis: This typically shows characteristic interlobular septal thickening on CT and has a more subacute presentation. It wouldn't typically cause acute RV strain without visible CT findings.\n\nD. Chemotherapy-associated pulmonary veno-occlusive disease (PVOD): This is rare and typically associated with certain chemotherapy agents. It would show specific CT findings like centrilobular ground-glass opacities and septal thickening.\n\nE. Metastatic tumor thrombus in pulmonary arteries: This would typically be visible on CT angiography as filling defects, similar to regular PE.\n\nThe key connection: The bone marrow infiltration confirms widespread tumor dissemination with tumor cells in the bloodstream. Combined with acute respiratory symptoms, RV strain, and NEGATIVE CT angiography, this strongly suggests tumor microembolism - where microscopic tumor cells lodge in the pulmonary microvasculature, causing increased pulmonary vascular resistance and RV strain, but are too small to be detected on standard CT angiography.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-003", "question": "A 28-year-old man presents to the emergency department with severe headache, vomiting, and photophobia after a recent hiking trip. CSF analysis shows lymphocytic pleocytosis, elevated protein, and normal glucose. PCR for common viruses is negative, but serology reveals antibodies to a rare pathogen. What is the most appropriate initial management?", "options": ["Intravenous acyclovir for presumed herpes encephalitis", "Empiric antibiotics for bacterial meningitis", "Supportive care with close monitoring", "Corticosteroids to reduce inflammation", "Antifungal therapy targeting endemic mycoses"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests lymphocytic meningitis from a rare arbovirus like Jamestown Canyon virus, where supportive care is the mainstay as no specific antiviral exists. Acyclovir is for herpes, unnecessary here with negative PCR. Antibiotics are for bacterial etiologies, ruled out by CSF profile.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 28-year-old man with headache, vomiting, photophobia (classic meningitis triad)\n- Recent hiking trip (exposure history)\n\nCSF Findings:\n- Lymphocytic pleocytosis\n- Elevated protein\n- Normal glucose\n- PCR for common viruses is NEGATIVE\n- Serology positive for a \"rare pathogen\"\n\nAnalysis of CSF pattern:\nThe CSF profile (lymphocytic pleocytosis, elevated protein, normal glucose) is consistent with:\n- Viral meningitis\n- Early bacterial meningitis\n- Fungal meningitis\n- Tuberculous meningitis\n- Certain tick-borne illnesses\n\nThe normal glucose makes bacterial and fungal causes less likely (they typically cause low glucose). The negative viral PCR and positive serology for a \"rare pathogen\" after hiking suggests this could be something like:\n- Colorado tick fever\n- Lymphocytic choriomeningitis virus (LCMV)\n- Other arboviral infections\n\nEvaluating options:\n\nA. IV Acyclovir - Used for HSV encephalitis, but PCR is negative and the presentation is more meningitis than encephalitis. HSV typically shows temporal lobe involvement.\n\nB. Empiric antibiotics - Bacterial meningitis typically shows neutrophilic pleocytosis and low glucose, not this pattern.\n\nC. Supportive care with close monitoring - Most viral meningitides are self-limiting and managed supportively. Given the CSF profile suggests viral etiology and serology confirms a pathogen (likely viral given the pattern), supportive care is appropriate.\n\nD. Corticosteroids - Not first-line for viral meningitis; used adjunctively in bacterial meningitis or certain inflammatory conditions.\n\nE. Antifungal therapy - Fungal meningitis typically shows low glucose; less likely here.\n\nGiven the classic viral meningitis CSF profile, negative bacterial/common viral PCR, and identification of a rare pathogen via serology (likely a self-limiting viral illness acquired during hiking), supportive care is the most appropriate initial management.\n\nThe answer is (C)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-004", "question": "A 7-year-old boy with autism spectrum disorder presents with recurrent episodes of staring spells and facial twitching. EEG shows multifocal epileptiform discharges, and MRI reveals subtle cortical dysplasia. Genetic testing identifies a de novo mutation. What is the most effective first-line therapy?", "options": ["Valproic acid for broad-spectrum coverage", "Levetiracetam to minimize behavioral side effects", "Carbamazepine for focal seizures", "Vagus nerve stimulation as adjunct", "Ketogenic diet initiation"], "answer": "B", "answer_index": 1, "explanation": "In epileptic encephalopathy due to mutations like SCN8A, levetiracetam is preferred for its efficacy and lower risk of exacerbating behavioral issues in autism. Valproic acid can worsen aggression, while carbamazepine may aggravate generalized features. Dietary therapies are second-line.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nPatient Profile:\n- 7-year-old boy with autism spectrum disorder (ASD)\n- Recurrent staring spells and facial twitching (suggesting focal seizures with impaired awareness)\n- EEG: multifocal epileptiform discharges\n- MRI: subtle cortical dysplasia\n- De novo genetic mutation identified\n\nKey Considerations:\n\n1. Seizure type: The presentation suggests focal seizures (staring spells with facial twitching), possibly with secondary generalization given multifocal discharges.\n\n2. Cortical dysplasia with multifocal discharges: This suggests a structural etiology with potentially drug-resistant epilepsy.\n\n3. Autism spectrum disorder: Behavioral side effects are an important consideration.\n\nEvaluating Options:\n\nA. Valproic acid: Broad-spectrum antiepileptic that covers both focal and generalized seizures. Effective for multifocal epilepsy. However, has metabolic side effects and is not typically first-line in children.\n\nB. Levetiracetam: Broad-spectrum coverage, effective for focal and generalized seizures. Important consideration here is that it can cause behavioral side effects (irritability, aggression) which could be problematic in a child with ASD. However, it's often well-tolerated and is commonly used first-line.\n\nC. Carbamazepine: Good for focal seizures but can worsen certain generalized seizure types. With multifocal discharges, this might not be ideal and could potentially exacerbate some seizure types.\n\nD. Vagus nerve stimulation: This is an adjunct therapy, not first-line treatment.\n\nE. Ketogenic diet: While effective, especially in drug-resistant epilepsy, it's typically not first-line therapy.\n\nBest Answer:\nGiven the multifocal nature of the epilepsy and the need for broad-spectrum coverage, valproic acid provides the most comprehensive coverage for both focal and potentially generalized seizures. While levetiracetam is often used, its behavioral side effects are particularly concerning in a child with ASD. Valproic acid offers broad-spectrum efficacy for this complex presentation.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-005", "question": "A 55-year-old man with Parkinson's disease develops sudden onset of dysarthria and hemiparesis. MRI shows acute infarction in the lenticulostriate territory, but vessel imaging is normal. Coagulation studies reveal an abnormality. What is the underlying mechanism?", "options": ["Cardioembolic stroke from atrial fibrillation", "Lacunar infarct due to small vessel disease", "Thrombotic stroke from antiphospholipid syndrome", "Vasculitis mimicking stroke", "Embolic stroke from levodopa-induced arrhythmia"], "answer": "C", "answer_index": 2, "explanation": "Antiphospholipid syndrome can cause thrombotic strokes in atypical territories without large vessel occlusion, especially with coagulation abnormalities. Lacunar infarcts are typically hypertensive, not matching this profile. Cardioembolism usually involves larger territories or arrhythmias, absent here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nKey findings:\n- 55-year-old man with Parkinson's disease\n- Sudden onset dysarthria and hemiparesis (stroke symptoms)\n- MRI shows acute infarction in lenticulostriate territory\n- Vessel imaging is NORMAL\n- Coagulation studies reveal an ABNORMALITY\n\nThe critical clues are:\n1. Normal vessel imaging - this argues against large vessel atherosclerosis\n2. Abnormal coagulation studies - this points to a hypercoagulable state\n3. Lenticulostriate territory - deep brain structures supplied by small penetrating arteries\n\nLet me evaluate each option:\n\nA. Cardioembolic stroke from atrial fibrillation - AF wouldn't cause coagulation abnormalities directly; it's a rhythm issue, not a coagulation disorder\n\nB. Lacunar infarct due to small vessel disease - This is common in lenticulostriate territory, but wouldn't explain the coagulation abnormality\n\nC. Thrombotic stroke from antiphospholipid syndrome - This would cause coagulation abnormalities (prolonged PTT, positive lupus anticoagulant, anticardiolipin antibodies), can cause strokes in any territory including small vessels, and vessel imaging could be normal as it's a prothrombotic state rather than vessel wall disease\n\nD. Vasculitis mimicking stroke - Would typically show vessel abnormalities on imaging\n\nE. Embolic stroke from levodopa-induced arrhythmia - Levodopa can cause orthostatic hypotension but arrhythmias causing embolic stroke are not a typical complication, and this wouldn't explain coagulation abnormalities\n\nThe combination of:\n- Stroke with normal vessel imaging\n- Abnormal coagulation studies\n- Points strongly to a hypercoagulable/prothrombotic condition\n\nAntiphospholipid syndrome causes a hypercoagulable state with characteristic coagulation abnormalities and can cause arterial thrombosis leading to stroke, even in small vessel territories.\n\nThe answer is (C)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-006", "question": "In the ICU, a 70-year-old patient with septic shock from pneumonia remains hypotensive despite vasopressors and fluids. Adrenal function testing shows a blunted cortisol response, but random cortisol is normal. What is the next step in management?", "options": ["Initiate hydrocortisone replacement therapy", "Add fludrocortisone for mineralocorticoid support", "Perform cosyntropin stimulation test", "Switch to alternative vasopressor like vasopressin", "Administer ascorbic acid and thiamine"], "answer": "D", "answer_index": 3, "explanation": "Relative adrenal insufficiency in sepsis may not respond to steroids if cortisol is normal; switching to vasopressin addresses vasoplegia more effectively. Hydrocortisone is controversial without clear deficiency. Cosyntropin is already implied by blunted response.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case of a 70-year-old patient with septic shock from pneumonia.\n\nKey findings:\n- Septic shock refractory to vasopressors and fluids\n- Blunted cortisol response (suggesting relative adrenal insufficiency)\n- Normal random cortisol level\n\nThis presentation is consistent with critical illness-related corticosteroid insufficiency (CIRCI), previously known as relative adrenal insufficiency. In septic shock, even \"normal\" cortisol levels may be inadequate for the degree of stress, and a blunted response to stimulation indicates the adrenal glands cannot mount an appropriate response.\n\nLet me evaluate the options:\n\nA. Initiate hydrocortisone replacement therapy - The Surviving Sepsis Campaign guidelines recommend hydrocortisone (200 mg/day IV) for patients with septic shock who remain hypotensive despite adequate fluid resuscitation and vasopressor therapy. The blunted cortisol response supports this intervention.\n\nB. Add fludrocortisone - While some studies have used fludrocortisone with hydrocortisone, hydrocortisone alone at stress doses provides adequate mineralocorticoid activity. This is not the first-line approach.\n\nC. Perform cosyntropin stimulation test - The patient already has evidence of blunted cortisol response. Current guidelines suggest not delaying treatment to perform additional testing in refractory septic shock.\n\nD. Switch to alternative vasopressor - While vasopressin can be added as a second-line agent, the question specifically points to adrenal dysfunction as the issue to address.\n\nE. Administer ascorbic acid and thiamine - This refers to the \"metabolic resuscitation\" approach, but evidence for this is not as strong as for corticosteroids in refractory septic shock with adrenal insufficiency.\n\nGiven the clinical scenario of refractory septic shock with evidence of adrenal insufficiency (blunted response), the most appropriate next step is to initiate hydrocortisone therapy.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-007", "question": "A 38-year-old woman with chronic myeloid leukemia on dasatinib develops pleural effusions and fatigue. Cytogenetic analysis shows additional clonal evolution. What is the most appropriate therapeutic adjustment?", "options": ["Switch to imatinib to reduce pulmonary toxicity", "Add interferon-alpha for immunomodulation", "Initiate ponatinib for resistant mutations", "Dose reduce dasatinib and monitor", "Proceed to allogeneic stem cell transplant"], "answer": "C", "answer_index": 2, "explanation": "Clonal evolution in CML on dasatinib often indicates T315I mutation, for which ponatinib is effective despite pulmonary risks. Imatinib lacks potency against advanced disease. Transplant is considered but not first-line without failure of second-generation TKIs.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "Let me analyze this case systematically.\n\nThe patient has:\n1. Chronic myeloid leukemia (CML) on dasatinib\n2. Pleural effusions (a known side effect of dasatinib)\n3. Fatigue\n4. Clonal evolution on cytogenetic analysis\n\nThe key finding here is clonal evolution, which indicates disease progression and resistance to current therapy. This is a significant concern as it suggests the leukemia is no longer adequately controlled by dasatinib.\n\nLet me evaluate each option:\n\nA. Switch to imatinib - While this would address the pleural effusion (dasatinib toxicity), imatinib is a less potent TKI. Switching to a weaker agent when there's evidence of clonal evolution/resistance would not be appropriate.\n\nB. Add interferon-alpha - This is sometimes used in combination therapy but is not the standard approach for resistant disease with clonal evolution.\n\nC. Initiate ponatinib - Ponatinib is a third-generation TKI that is effective against many resistant mutations, including T315I. However, clonal evolution alone doesn't necessarily indicate a specific mutation requiring ponatinib.\n\nD. Dose reduce dasatinib - This might help with pleural effusions but would be inappropriate given evidence of disease progression (clonal evolution).\n\nE. Proceed to allogeneic stem cell transplant - Clonal evolution in CML indicates disease progression and is associated with a worse prognosis. It's considered a warning sign of accelerated phase or transformation. According to treatment guidelines, clonal evolution represents a failure of TKI therapy and is an indication for considering allogeneic stem cell transplant, especially in younger patients who are transplant candidates.\n\nGiven that this 38-year-old patient has evidence of clonal evolution (indicating TKI failure/resistance) and is relatively young, allogeneic stem cell transplant would be the most appropriate definitive therapy. Clonal evolution is a criterion for accelerated phase CML in some classifications and indicates the need for more aggressive intervention.\n\nThe answer is (E)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-008", "question": "A 35-year-old woman in the emergency department collapses after ingesting an unknown substance. She has bradycardia, hypotension, and miosis. Atropine provides partial response, but symptoms recur. What is the definitive antidote?", "options": ["Pralidoxime for organophosphate poisoning", "N-acetylcysteine for acetaminophen", "Flumazenil for benzodiazepine overdose", "Physostigmine for anticholinergic toxicity", "Hydroxocobalamin for cyanide"], "answer": "A", "answer_index": 0, "explanation": "This cholinergic toxidrome suggests organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase after initial atropine. Atropine alone is insufficient for severe cases. Other antidotes target different mechanisms not fitting the presentation.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nThe patient presents with:\n- Bradycardia\n- Hypotension\n- Miosis (constricted pupils)\n- Partial response to atropine with recurrence of symptoms\n\nThis triad of bradycardia, hypotension, and miosis is classic for cholinergic toxidrome, which is seen in organophosphate poisoning. The \"SLUDGE\" symptoms (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) along with bradycardia and miosis are characteristic.\n\nThe fact that atropine provides only partial response and symptoms recur is key. Atropine is a muscarinic antagonist that treats the muscarinic effects of organophosphate poisoning, but it doesn't address the underlying problem - the inhibition of acetylcholinesterase.\n\nPralidoxime (2-PAM) is the definitive antidote for organophosphate poisoning because it:\n1. Reactivates acetylcholinesterase by removing the organophosphate from the enzyme\n2. Must be given before \"aging\" occurs (permanent binding)\n3. Works synergistically with atropine\n\nLet me rule out other options:\n- B: N-acetylcysteine is for acetaminophen toxicity (hepatotoxicity, not these symptoms)\n- C: Flumazenil for benzodiazepines (would cause CNS depression, respiratory depression, not miosis)\n- D: Physostigmine is for anticholinergic toxicity (which causes tachycardia, mydriasis - opposite symptoms)\n- E: Hydroxocobalamin for cyanide (causes altered mental status, metabolic acidosis, not miosis)\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-009", "question": "A 12-year-old girl with juvenile idiopathic arthritis on etanercept develops fever, rash, and lymphadenopathy. Serology is positive for a virus, but PCR on lymph node biopsy reveals clonal T-cell population. What is the most likely complication?", "options": ["Drug reaction with eosinophilia and systemic symptoms", "EBV-associated lymphoproliferative disorder", "Macrophage activation syndrome", "Secondary hemophagocytic lymphohistiocytosis", "TNF inhibitor-induced lymphoma"], "answer": "E", "answer_index": 4, "explanation": "TNF inhibitors like etanercept increase risk of T-cell lymphomas, especially with clonal populations on biopsy, beyond viral associations. EBV-LPD is B-cell predominant. MAS and HLH are cytokine-driven without clonality.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nKey clinical features:\n- 12-year-old girl with juvenile idiopathic arthritis (JIA)\n- On etanercept (a TNF inhibitor)\n- Presents with fever, rash, and lymphadenopathy\n- Positive viral serology\n- PCR on lymph node biopsy shows clonal T-cell population\n\nThe combination of:\n1. TNF inhibitor therapy (etanercept)\n2. Positive viral serology (likely EBV given the context)\n3. Clonal T-cell population in lymph node\n\nThis presentation is highly suggestive of a lymphoproliferative disorder. TNF inhibitors are known to increase the risk of lymphoproliferative disorders, particularly in the setting of EBV infection.\n\nLet me consider each option:\n\nA. DRESS (Drug reaction with eosinophilia and systemic symptoms) - Would not typically show clonal T-cell population on biopsy\n\nB. EBV-associated lymphoproliferative disorder - This fits well with viral serology positivity and clonal lymphocyte population, and is associated with immunosuppression from TNF inhibitors\n\nC. Macrophage activation syndrome - While this can occur in JIA, it wouldn't typically show clonal T-cell population; it would show hemophagocytosis\n\nD. Secondary hemophagocytic lymphohistiocytosis - Similar to MAS, wouldn't explain the clonal T-cell population\n\nE. TNF inhibitor-induced lymphoma - While TNF inhibitors are associated with lymphoma risk, the question specifically mentions positive viral serology, pointing toward a virus-associated process\n\nThe presence of positive viral serology combined with clonal T-cell population in a patient on immunosuppressive therapy (TNF inhibitor) most strongly suggests EBV-associated lymphoproliferative disorder. EBV is well-known to cause lymphoproliferative disorders in immunocompromised patients, and TNF inhibitors increase this risk.\n\nThe answer is B"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-010", "question": "A 68-year-old man with amyotrophic lateral sclerosis presents with progressive dysphagia and aspiration. Videofluoroscopy shows pharyngeal weakness. Non-invasive ventilation is in use. What is the most appropriate intervention?", "options": ["Percutaneous endoscopic gastrostomy placement", "Botulinum toxin injection into cricopharyngeus", "Tracheostomy for airway protection", "Speech therapy with swallowing exercises", "Pharmacologic enhancement with edrophonium"], "answer": "B", "answer_index": 1, "explanation": "In ALS with cricopharyngeal dysfunction causing dysphagia, botulinum toxin relaxes the muscle to improve swallowing, a targeted approach before invasive feeding. PEG is for nutrition but not dysphagia mechanism. Tracheostomy addresses ventilation, not swallowing.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case of a 68-year-old man with ALS presenting with progressive dysphagia and aspiration.\n\nKey clinical features:\n- ALS (progressive neurodegenerative disease)\n- Progressive dysphagia\n- Aspiration (indicating risk of aspiration pneumonia)\n- Pharyngeal weakness on videofluoroscopy\n- Already on non-invasive ventilation (NIV)\n\nLet me evaluate each option:\n\nA. Percutaneous endoscopic gastrostomy (PEG) placement - This is the standard of care for ALS patients with dysphagia and aspiration risk. It provides enteral nutrition while bypassing the compromised swallowing mechanism. Guidelines recommend PEG placement while respiratory function is still adequate (FVC >50%), and since he's on NIV, this suggests his respiratory function is declining, making timely PEG placement important.\n\nB. Botulinum toxin injection into cricopharyngeus - This is used for cricopharyngeal dysfunction/achalasia, not for generalized pharyngeal weakness seen in ALS. The problem here is pharyngeal weakness, not cricopharyngeal spasm.\n\nC. Tracheostomy for airway protection - While this protects the airway, it doesn't address nutrition needs and is a more invasive intervention. It's typically reserved for ventilatory failure rather than dysphagia management.\n\nD. Speech therapy with swallowing exercises - In progressive neurodegenerative diseases like ALS, swallowing exercises have limited benefit as the underlying disease continues to progress. This may provide some temporary benefit but won't address the aspiration risk adequately.\n\nE. Pharmacologic enhancement with edrophonium - This is used for myasthenia gravis diagnosis/treatment, not ALS. ALS is a motor neuron disease, not a neuromuscular junction disorder.\n\nFor ALS patients with progressive dysphagia and aspiration risk, PEG placement is the most appropriate intervention to maintain nutrition and reduce aspiration risk.\n\nThe answer is (A)"}]